TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23809766
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily in cycles of 3 weeks on/1 week off treatment until disease progression, unacceptable toxicity, death or patient/physician decision to discontinue.
Study: 23810467
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg daily and olaparib 200 mg BID
Study: 23810788
Drug: Niraparib 30
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 30 mg/day
Study: 23810788
Drug: Niraparib 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 60 mg/day
Study: 23810788
Drug: Niraparib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 400 mg/day
Study: 23810788
Drug: Niraparib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (various doses)
Study: 23810788
Drug: Niraparib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (doses >80 mg/day)
Study: 23810788
Drug: Niraparib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (doses >60 mg/day)
Study: 23812930
Drug: Lenalidomide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (15 mg/day on days 1-14) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Study: 23812930
Drug: Lenalidomide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (15 mg/day)
Study: 23812932
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg intravenous every 21 days)
Study: 23813757
Drug: Skin intrinsic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin intrinsic fluorescence (SIF) in the intensive treatment group
Study: 23813757
Drug: Skin intrinsic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin intrinsic fluorescence (SIF) in the conventional treatment group
Study: 23815981
Drug: FBTA05 (Bi20),
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody in combination with donor lymphocyte infusion (DLI)
Study: 23816016
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice a day for 1 month for patients ≥70 kg; 0.5 mg once for patients <70 kg or intolerant)
Study: 23816920
Drug: Omalizumab (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (n = 4), administered every 2-4 weeks over 24 weeks
Study: 23816920
Drug: Placebo (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n = 4), administered every 2-4 weeks over 24 weeks
Study: 23816963
Drug: Afatinib 50
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 50 mg per day
Study: 23817375
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) at 50 mg daily for 5 days followed by DTG with prednisone at 60 mg daily for 10 days (5 days high-dose followed by 5-day taper)
Study: 23817375
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) at 50 mg daily for 5 days
Study: 23817721
Drug: Dendritic cell-based
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell-based vaccine targeting CSCs
Study: 23817974
Drug: TAK-285 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-285 (400 mg twice daily)
Study: 23818263
Drug: Nonadjuvant influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvant influenza A H1N1 vaccine in juvenile SLE patients
Study: 23818263
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls vaccinated with nonadjuvant influenza A H1N1 vaccine
Study: 23820296
Drug: Conservative Treatment
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Treatment (Control)
Study: 23822525
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to initiation of adequate medical therapy
Study: 26696749
Drug: Panobinostat treatment
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat treatment
Study: 23823198
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interleukin-16 and 10-minute Apgar score
Study: 23824037
Drug: Citrate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate infusion in critically ill patients with AKI
Study: 23824037
Drug: Citrate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate infusion in healthy volunteers
Study: 23824363
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) delivering accelerated partial breast irradiation (APBI) at a dose of 38.5 Gy in 10 equal fractions delivered twice daily.
Study: 23824978
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) treatment after 24 months
Study: 23824978
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) treatment after 60 months
Study: 23824978
Drug: Cumulative CAB
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative CAB dose
Study: 23827886
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment for 10 weeks
Study: 23828252
Drug: 1,020 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,020 mg of ferumoxytol administered over 15 min
Study: 23829485
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion of veltuzumab (80-320 mg)
Study: 23829485
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injections of veltuzumab (80-320 mg)
Study: 23829485
Drug: Both IV
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IV and SC administration of veltuzumab
Study: 23829485
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injections of veltuzumab
Study: 23829485
Drug: Veltuzumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veltuzumab treatment
Study: 23830159
Drug: Acetylcholine (Ach)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (Ach) infusion (10(-6) to 10(-4))
Study: 23830159
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (200 μg)
Study: 23831416
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (cisplatin 80 mg/m(2) on day 1, cisplatin 70 mg/m(2) on days 8, 15, 29, 36, 43, 57, 64; doxorubicin 30 mg/m(2) on days 8, 9, 36, 37, 57, 58) followed by surgery.
Study: 23831416
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (doxorubicin 20 mg/m(2) on days 1, 2, 22, 23, 43, 44; carboplatin AUC 6·6 mg/mL per min on days 1, 22, 43) for patients who did not receive cycle B.
Study: 23831416
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen (including preoperative and postoperative chemotherapy).
Study: 23831756
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Study: 23831756
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Study: 23831756
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Study: 23831756
Drug: Oral cavity
Normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cavity contamination after smoking or oromucosal spray
Study: 23833120
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose chloroquine (5 mg/kg)
Study: 23837399
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (three doses)
Study: 23838219
Drug: Acute medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute medicine wards
Study: 23839484
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg co-administered with bosutinib 400 mg
Study: 23839484
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg alone
Study: 23840618
Drug: MVA85A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A vaccine (first dose) in ART naïve subjects
Study: 23840618
Drug: MVA85A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A vaccine (second dose) in ART naïve subjects
Study: 23840618
Drug: MVA85A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A vaccine (first dose) in subjects on ART
Study: 23840618
Drug: MVA85A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A vaccine (two doses) in ART naïve subjects
Study: 23841031
Drug: Rigosertib (ON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigosertib (ON 01910.Na) administered as a 3-day continuous infusion every 2 weeks at escalating doses (50, 100, 150, 250, 325, 400, 650, 850, 1,050, 1,375, 1,700 mg/m(2)/24h).
Study: 23845947
Drug: Lentiviral gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lentiviral gene therapy using a lentiviral vector encoding functional WASP
Study: 23845948
Drug: Lentiviral gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lentiviral gene therapy using a lentiviral vector to transfer a functional ARSA gene into hematopoietic stem cells (HSCs)
Study: 23846776
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral dose of dabrafenib
Study: 23846776
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) microdose of 50 µg radiolabeled dabrafenib
Study: 23847271
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (endoscopic therapy combined with non-selective β-blockers and anticoagulants)
Study: 23850908
Drug: Successful cardioversion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful cardioversion without anticoagulation or peri-procedural heparin therapy
Study: 23851911
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily plus Darunavir/Ritonavir 800/100 mg once daily
Study: 23855804
Drug: Cetuximab administered
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab administered as loading dose and then weekly during radiotherapy (exact dosage not specified)
Study: 23855804
Drug: Intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-modulated radiation therapy (IMRT) or 3D-dimensional radiation therapy
Study: 23856024
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for inherited surfactant metabolism disorders (specific treatment details not provided)
Study: 23856681
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of alternate-day aspirin
Study: 23857959
Drug: Sepantronium Bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sepantronium Bromide (10 mg/m(2)/day, continuous intravenous infusion over 72 hours)
Study: 23857959
Drug: Carboplatin (AUC6)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC6) and Paclitaxel (200 mg/m(2))
Study: 23857966
Drug: Pazopanib (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (tablet formulation) administered once daily in 28-day cycles at four dose levels (275 to 600 mg/m(2))
Study: 23857966
Drug: Pazopanib (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (tablet formulation)
Study: 23860199
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 400 mg per day for 1 year
Study: 23860535
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m², Carboplatin AUC 5 mg/ml/min, Bevacizumab 15 mg/kg every 21 days for six cycles followed by maintenance Bevacizumab
Study: 23860537
Drug: Lenvatinib 4
Normalized name: lenvatinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 4 mg BID with carboplatin/paclitaxel
Study: 23860537
Drug: Lenvatinib 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 6 mg BID with carboplatin/paclitaxel
Study: 23861180
Drug: Citalopram (SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (SSRI treatment)
Study: 23861248
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² IV) administered at 3, 6, 9, and 12 months after transplantation
Study: 23863898
Drug: Reinduction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction therapy followed by alloHSCT
Study: 23866828
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg/day + reduced-dose cyclosporine
Study: 23866828
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g/day + standard dose cyclosporine
Study: 23867211
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohorts 1 and 2)
Study: 23867211
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohort 2)
Study: 23867776
Drug: ROTEM analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROTEM analysis at T1 (10 min after heparin administration)
Study: 23868427
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of HPPH (4.0 mg/m2), followed by activation with 665-nm laser light in the surgical bed immediately after tumor resection.
Study: 23870704
Drug: Maribavir (MBV)
Normalized name: maribavir
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir (MBV) 400 mg p.o. twice per day
Study: 23872668
Drug: Allogeneic mesenchymal
Normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic mesenchymal stromal cells (MSCs) administered intravenously at a dosage of 2 × 10(6) cells/kg body weight weekly for 4 weeks.
Study: 23876210
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 or 1.0 mg)
Study: 23878115
Drug: Lapatinib (500-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (500-1500 mg/day) + Docetaxel (triweekly; 60-100 mg/m²) + Trastuzumab (weekly; 2 mg/kg fixed dose)
Study: 23878140
Drug: FLT3 N676K
Normalized name: Pim/flt3 kinase inhibitor sel24
DrugBank: SEL-24 (DB18082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT3 N676K mutation with concurrent FLT3-ITD
Study: 23879405
Drug: sorafenib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (2 x 400 mg/day orally) and pegylated interferon alpha-2b (3 μg/kg body weight 1 x/week subcutaneously)
Study: 23880820
Drug: PEP02 (MM-398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP02 (MM-398) 120 mg/m(-2) intravenous injection every 3 weeks
Study: 23881401
Drug: Proceed™ Ventral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proceed™ Ventral Patch (PVP™)
Study: 23883872
Drug: Intravenous tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tigecycline (100 mg for 30 min)
Study: 23886346
Drug: Cilostazol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (50 mg for 2 weeks, 100 mg for 6 weeks)
Study: 23887852
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg twice daily and Bortezomib 1.3 mg/m2 on days 1, 4, 8, 11 (21-day cycles)
Study: 23887852
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg twice daily and Bortezomib 1 mg/m2 on days 1, 4, 8, 11 (21-day cycles)
Study: 23890349
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein intake (0.98 ± 0.28 g/kg body weight in males; 0.95 ± 0.29 g/kg body weight in females)
Study: 23890998
Drug: High platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High platelet reactivity on aspirin
Study: 23891361
Drug: Ticagrelor (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (in addition to aspirin)
Study: 23891361
Drug: Clopidogrel (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (in addition to aspirin)
Study: 23892959
Drug: AZD7762 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7762 monotherapy (6 mg, 9 mg, 21 mg, 30 mg)
Study: 23892959
Drug: AZD7762 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7762 plus gemcitabine (1,000 mg/m2)
Study: 23892959
Drug: AZD7762 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7762 monotherapy
Study: 23892959
Drug: AZD7762 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7762 (all doses)
Study: 23893090
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (Lucentis) 0.5 mg/0.05 ml injections
Study: 23893090
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (Lucentis) injections
Study: 23894304
Drug: Irinotecan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 50 mg/m(2)/day for 5 days combined with vincristine 1.5 mg/m(2) on days 1 and 8, temozolomide 100 mg/m(2) on days 1-5, and bevacizumab 15 mg/kg on day 1, administered every 21 days for a maximum of 12 cycles
Study: 23894304
Drug: Irinotecan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 50 mg/m(2)/day for 5 days
Study: 23896965
Drug: Eltrombopag (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (12.5, 25, or 50 mg once daily)
Study: 23898383
Drug: PBMCs from
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMCs from IBS children cultured with 5 ng/mL LPS
Study: 23898383
Drug: PBMCs from
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMCs from healthy controls (HCs) cultured with 5 ng/mL LPS
Study: 23899439
Drug: DTG 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG 50 mg daily for 5-7 days
Study: 23900652
Drug: Biofeedback (BF)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofeedback (BF) alone or in combination with electrical stimulation (ES)
Study: 23901077
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine delivered on alternative dosing schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months)
Study: 23901077
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine delivered on the 0, 12, 24 month schedule
Study: 23901077
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine delivered on any of the alternative dosing schedules
Study: 23901077
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV vaccine delivered at 0 and 12 months
Study: 23903369
Drug: Tolvaptan (90/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (90/30 mg/day, split dose) for 3 weeks
Study: 23903369
Drug: Tolvaptan (90/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (90/30 mg/day, split dose)
Study: 23903897
Drug: Icrucumab (2-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icrucumab (2-12 mg/kg weekly, 15 mg/kg every other week, 20 mg/kg every third week)
Study: 23904461
Drug: TriMixDC-MEL (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriMixDC-MEL (intravenous synthetic mRNA electroporated dendritic cell immunotherapy)
Study: 23905663
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of strength training and endurance training (n = 30)
Study: 23905663
Drug: Careful treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Careful treatment including diet and physical recommendations (n = 29)
Study: 23907406
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m² for 5 days), Valproic Acid (20 mg/kg for 7 days), Carboplatin (AUC 3.0 starting in second cycle)